tbuckley/cabot-search huggingface dataset:
SAT0104 Treatment with methotrexate in rheumatoid arthritis patients on stable biological treatment gives better outcomes over time
Authors: N. Boone, A. Sepriano, R. Janknegt, H. van derKuy, R. Peeters, R. Landewé
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In patients with rheumatoid arthritis (RA) biological-Disease Modifying Anti-Rheumatic Drugs (bDMARDs) should be used preferentially in combination with methotrexate (MTX) as prescribed by EULAR<sup>[1]</sup>. The longitudinal treatment-effect of combination treatment compared to bDMARD monotherapy in daily clinical practice is not yet well known. <h3>Objectives</h3> To test in a registry of patients with RA the longitudinal effect of combination therapy (i.e. MTX and bDMARDs) compared to monotherapy (i.e. bDMARDs only) on the likelihood to be in clinical remission over time. <h3>Methods</h3> Adult RA patients on stable treatment with conventional synthetic disease modifying drugs (csDMARDs) and/or biologic DMARDs (bDMARDs) were followed in one centre. During clinical visits every 3 months up to 3 years rheumatologists/research nurses collected clinical- and medication data. The effect of a (time-varying) combination treatment strategy (i.e. MTX and bDMARDs) as compared to monotherapy with bDMARDs on the likelihood to be on DAS28 (≤2.6) and RAPID3 (0-30) (≤3) remission was tested in longitudinal binomial generalized estimating equations (GEE) models (one model per outcome). In addition, the effect of combination therapy compared to monotherapy on each individual component of DAS28 [tender joint count (TJC; 0-28); swollen joint count (SJC; 0-28); patient global assessment (PGA; 0-10) and ESR (mm/h)] was tested in separate longitudinal linear GEE models. All models were adjusted for possible confounders selected 'a priori' on clinical grounds: age, gender, drugs for comorbidities (yes/no), oral steroids (yes/no) and NSAID (yes/no). <h3>Results</h3> A total of 330 patients were included [mean (SD) age: 62 (12) years, 68% female, baseline mean (SD) DAS28: 3.3 (1.4) and RAPID3: 11.5 (6)]. The mean (SD) follow-up period and disease duration were 10.7 (9.7) months and 11.2 (9.6) years respectively. Combination treatment was significantly associated with a 55% higher likelihood to be in DAS28-remission (but not RAPID3-remission) over time compared with bDMARDs monotherapy (table 1). In addition, combination treatment resulted in a decrease on the SJC over time as compared to monotherapy [β=-0.91 (95% CI: -1.77; -0.06)]. No significant differences between the two treatment strategies were seen for the other DAS28 components. <h3>Conclusions</h3> These results give support to the recommendation that continuing MTX in patients with RA under biological therapy increases the likelihood of clinical remission (especially when assessed with objective measures) and thus should be encouraged. <h3>Reference:</h3> [1] Smolen JS, et al. Ann Rheum Dis 2014;73:492-509. <h3>Disclosure of Interest:</h3> None declared
American Academy of Pediatrics Says No More Spanking or Harsh Verbal Discipline
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A High-Throughput Screening Approach to Identify Therapeutics for the Treatment of Diamond-Blackfan Anaemia
Authors: Lorena Nunez Villacis, Sheren J Al-Obaidi, Piyush Madhamshettiwar, Nadine Hein, Jun Chen, Priscilla Soo, Perlita Poh, Megan Pavy, Kaylene J Simpson, Thomas John Gonda, Richard B Pearson, Johan Flygare, Katherine M Hannan, Amee J George, Ross Hannan
Journal: Blood (2018)
Loss of BCAA Catabolism during Carcinogenesis Enhances mTORC1 Activity and Promotes Tumor Development and Progression
Authors: Russell E. Ericksen, Siew Lan Lim, Eoin McDonnell, Wai Ho Shuen, Maya Vadiveloo, Phillip J. White, Zhaobing Ding, Royston Kwok, Philip Lee, George K. Radda, Han Chong Toh, Matthew D. Hirschey, Weiping Han
Journal: Cell Metabolism (2019)
Neural Responsivity to Food Cues in Patients With Unmedicated First-Episode Psychosis
Authors: Faith Borgan, Owen O’Daly, Karen Hoang, Mattia Veronese, Dominic Withers, Rachel Batterham, Oliver Howes
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Schizophrenia is associated with a reduced life expectancy of 15 to 20 years owing to a high prevalence of cardiometabolic disorders. Obesity, a key risk factor for the development of cardiometabolic alterations, is more prevalent in individuals with schizophrenia. Although obesity is linked to the altered reward processing of food cues, no studies have investigated this link in schizophrenia without the confounds of antipsychotics and illness chronicity. <h3>Objective</h3> To investigate neural responsivity to food cues in first-episode psychosis without the confounds of antipsychotic medication or illness chronicity. <h3>Design, Setting, and Participants</h3> A case-control study was conducted from January 31, 2015, to September 30, 2018, in London, United Kingdom, of 29 patients with first-episode psychosis who were not taking antipsychotic medication and 28 matched controls. <h3>Main Outcomes and Measures</h3> Participants completed a food cue paradigm while undergoing a functional magnetic resonance imaging scan. Neural activation was indexed using the blood oxygen level–dependent hemodynamic response. The Dietary Instrument for Nutrition Education was used to measure diet, and the International Physical Activity Questionnaire was used to measure exercise. <h3>Results</h3> There were no significant differences in age, sex, or body mass index between the 29 patients (25 men and 4 women; mean [SD] age, 26.1 [4.8] years) and 28 controls (22 men and 6 women; mean [SD] age, 26.4 [5.5] years). Relative to controls, patients consumed more saturated fat (<i>t</i><sub>46</sub> = –3.046;<i>P</i> = .004) and undertook less high-intensity (<i>U</i> = 304.0;<i>P</i> = .01) and low-intensity (<i>U</i> = 299.5;<i>P</i> = .005) weekly exercise. There were no group differences in neural responses to food vs nonfood cues in whole-brain or region-of-interest analyses of the nucleus accumbens, insula, or hypothalamus. Body mass index was inversely correlated with the mean blood oxygen level–dependent signal in the nucleus accumbens in response to food vs nonfood cues in controls (<i>R</i> = –0.499;<i>P</i> = .01) but not patients (<i>R</i> = 0.082;<i>P</i> = .70). <h3>Conclusions and Relevance</h3> Relative to controls, patients with first-episode psychosis who were not taking antipsychotic medication consumed more saturated fat and showed an altered association between body mass index and neural response to food cues in the absence of differences in neural responses to food cues. These findings highlight how maladaptive eating patterns and alterations in the association between body mass index and neural responses to food cues are established early in the course of schizophrenia.
Abstract 20358: The mRNA Binding Protein Zfp36l1 Regulates Cardiac Development Genes and is Essential for Cardiac Function in Adulthood
Authors: Adam De Jesus, Jason S Shaprio, Hsiang-Chun Chang, Shang Meng, Kai Xu, Lisa D Wilsbacher, Hossein Ardehali
Journal: Circulation (2017)

Introduction: Several key transcription factors are known to orchestrate the majority of cardiac morphogenesis during embryonic development. However, the post-transcriptional regulation of these es...
Doing no harm in mindfulness-based programs: Conceptual issues and empirical findings
Authors: Ruth Baer, Catherine Crane, Edward Miller, Willem Kuyken
Journal: Clinical Psychology Review (2019)

The benefits of empirically supported mindfulness-based programs (MBPs) are well documented, but the potential for harm has not been comprehensively studied. The available literature, although too small for a systematic review, suggests that the question of harm in MBPs needs careful attention. We argue that greater conceptual clarity will facilitate more systematic research and enable interpretation of existing findings. After summarizing how mindfulness, mindfulness practices, and MBPs are defined in the evidence-based context, we examine how harm is understood and studied in related approaches to physical or psychological health and wellbeing, including psychotherapy, pharmacotherapy, and physical exercise. We also review research on harmful effects of meditation in contemplative traditions. These bodies of literature provide helpful parallels for understanding potential harm in MBPs and suggest three interrelated types of factors that may contribute to harm and require further study: program-related factors, participant-related factors, and clinician- or teacher-related factors. We discuss conceptual issues and empirical findings related to these factors and end with recommendations for future research and for protecting participants in MBPs from harm.
AB0718 Autologous hematopoietic stem -cell transplantation in severe and refractory diffused systemic sclerosis. long-term study in a single reference centre
Authors: A. Ruiz Roman, B. Atienza Mateo, V. Calvo del Rio, M.A. Gonzalez-Gay Mantecón, R. Blanco Alonso
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Pharmacological therapy does not reverse the natural course of systemic sclerosis (SS). Autologous hematopoietic stem-cell transplantation(AHSCT) has been used in refractory autoimmune diseases, including SS. The autologous hematopoietic stem-cell transplantation is based on the ablation of the immunoreactive system with high doses of chemotherapy and a subsequent regeneration of the immune system. <h3>Objectives</h3> Study of the efficacy of autologous hematopoietic stem-cell transplantation in a cohort of patients with SS from a referral centre. <h3>Methods</h3> Descriptive study of patients with SS (ACR/<sup>EULAR 2013</sup> criteria) treated with autologous hematopoietic stem-cell transplantation in a single reference centre between 2002 and 2017. These clinical variables were reviewed (Raynaud's phenomenon, pulmonary interstitial involvement, digital ulcers, digestive alterations, presence of sclerodermic renal crisis) and activity index variables (modified Rodnan score, HAQ-DI, SHAQ-VAS). <h3>Results</h3> Four patients were included (75% women). The median age at the time of the AHSCT was 36.5 years (range 27–51). In all cases, the initial diagnosis was diffuse cutaneous ES, refractory to corticosteroids and at least one DMARD. Prior to autologous hematopoietic stem-cells transplantation, the clinical manifestations presented were a) severe Raynaud's phenomenon (100%) with significant joint and cutaneous involvement; b) digital ulcers (50%); c) interstitial lung disease (50%) and d) sclerodermal renal crisis (25%). In 3 of the cases (75%) the antitopoisomerase antibodies were positive. The conditioning treatment for the autologous hematopoietic stem-cells transplantation was cyclophosphamide at high doses (50 mg/kg x4 days) and anti-thymocyte globulin. In 3 patients (75%) there were slight post-transplant complications (febrile neutropenia, diarrhoea) after a median follow-up of 6.5 years (range 1–15). The response to AHSCT is summarised in table 1. All patients showed values &lt;1 in the Health Assessment Questionnaire on the Disability Index (HAQ-DI), in 75% with a modified Rodnan skin score (mRSS) lower than 7. <h3>Conclusions</h3> Autologous hematopoietic stem-cells transplantation can be a therapeutic option in refractory and severe SS. These hopeful data must be ratified in larger studies. <h3>Disclosure of Interest</h3> None declared
Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Matched or Mismatched 9/10 Unrelated Donors in Acute Lymphoblastic Leukemia in First Complete Remission: On Behalf of the ALWP of the EBMT
Authors: Noga Shem-Tov, Christophe Peczynski, Myriam Labopin, Maija Itälä-Remes, Didier Blaise, Hélène Labussière-Wallet, Gérard Socié, Nicolaus Kröger, Per Ljungman, Boris Afanasyev, Patrice Chevallier, Johanna Tischer, Grzegorz Helbig, Pavel Jindra, Sebastian Giebel, Mohamad Mohty, Arnon Nagler
Journal: Blood (2018)
AB1223 Ultrasonography examination of elbows is useful when combined with examination of pip and wrist joints
Authors: T. Nakajiama, M. Shimizu, M. Hashimoto, H. Yamamoto, R. Kawahara, S. Nakabo, R. Hiwa, Y. Gon, S. Funakoshi, Y. Nakamura, T. Sasai, T. Tomizawa, K. Nishitani, K. Murata, M. Tanaka, H. Ito, Y. Fujii, T. Mimori
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Because elbows are important joints for the function of upper limbs, the daily activity of the patients with rheumatoid arthritis (RA) may be impaired by synovitis of elbows. Although elbows are included into the 28 essential joints for evaluation of the disease activity of RA, ultrasonography (US) examination of elbows is not routinely performed and there have been a few surveys on the correlation between US scores of elbows and disease activity. <h3>Objectives</h3> To reveal whether there is a correlation between US scores of elbows and disease activity in the patients with RA. <h3>Methods</h3> We recruited 198 patients with RA form KURAMA cohort, which is the database of the patients with RA treated in the Kyoto University Hospital, and performed US examination of proximal interphalangeal (PIP) joints, metacarpophalangeal (MP) joints, wrist joints and elbow joints. Synovial hypertrophy is scored semiquantitatively on a scale of 0–3. We analysed correlations between the total scores of each component (PIP, MP, wrist and elbow) and clinical parameters. <h3>Results</h3> We found weak correlations between DAS28-ESR and the US scores of PIPs, MPs and wrists (rho=0.25, 0.21 and 0.29, respectively) whereas there was little correlation between DAS28-ESR and the US score of elbows (rho=0.16). However, multivariable analysis showed that the US scores of PIPs, wrists and elbows were independently associated with DAS28-ESR (p=0.021, 0.0027 and 0.025, respectively). US scores of elbows showed little or weak correlations with US scores of PIPs, MPs and wrists (rho=0.23, 0.16 and 0.11, respectively). <h3>Conclusions</h3> US examination of elbows may be useful to assess the disease activity of patients when combined with US examination of PIPs and wrists although US scores of elbows alone has a weak correlation with DAS28-ESR. US examination of elbows may detect the disease activity which is overlooked by the US examination of joints of hand. <h3>Disclosure of Interest</h3> None declared
Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy
Authors: Mee Y. Bartee, Parker C. Dryja, Eric Bartee
Journal: Journal for ImmunoTherapy of Cancer (2019)

Expression of PDL1 on the surface of tumor cells can blunt the efficacy of many cancer immunotherapies. For example, our lab has previously shown that tumors derived from malignant cells incapable of expressing PDL1 are highly susceptible to immunotherapy induced by oncolytic virus treatment while tumors derived from PDL1 capable cells are highly resistant. In patient biopsies, however, expression of PDL1 on malignant cells is often not uniform with some cells expressing PDL1 while others do not. Importantly, how this partial PDL1 positivity influences the outcomes of immunotherapy remains largely unknown. In the current work, we expand on our previous findings by generating partially PDL1 positive tumors in immune competent animals and asking what percentage of tumor cells must express PDL1 for a tumor to become functionally resistant to oncolytic treatment. Our results indicate that the responsiveness of partially PDL1<sup>+</sup> tumors correlates linearly with the percentage of PDL1 capable cells present at the initiation of treatment. Additionally, we observe that tumors which relapse after treatment display a significant increase in the numbers of PDL1 capable cells present suggesting that specific editing of mixed tumors might play a role in disease relapse. These data indicate that varying levels of PDL1 expression can play a significant role in the outcomes of oncolytic immunotherapy and challenges the concept that tumors should be viewed as simply PDL1<sup>+</sup> or PDL1<sup>−</sup>.
FRI0301 Serum exosomes involved in the progression of lupus nephritis
Authors: Z. Zhang, W. Xue, J. Ji, T. Fu, J. Yang, Z. Gu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE is a chronic autoimmune disease that systemically affects several important organs[.<sup>1</sup> Lupus nephritis (LN is one of the most severe complications of SLE[.<sup>2</sup> Exosomes are important mediators of biological information and play a part in the occurrence and development of various diseases including LN[.<sup>3</sup> <h3>Objectives</h3> The aim of study was to find whether exosomes participate in the pathogenesis of lupus nephritis. <h3>Methods</h3> We studied 10 patients with SLE but no LN,10 patients with LN and 10 healthy people which are in line with the SLE classification criteria of American College of Rheumatology diagnostic (ACR) in 1997 and the LN pathological classification of ISN and RPS in 2003. Exosomes were isolated from the serum by ultracentrifugation and confirmed by transmission electron microscope and western blot. The internalisation of exosomes was detected by immunofluorescence Then exosomes were injected into MRL/lpr mouse via the tail vein and co-cultured with mesangial cells. Flow cytometry was used to detect the alteration of cell cycle. The cell proliferation was determined by CCK-8 assay. The inflammatory cytokines (TNF-α, IL-6) and collagen I level in medium supernatant by ELISA, signal pathway by immunoblotting. Additionally, High-throughput sequencing was used to detect the expression of miRNAs in exosomes. <h3>Results</h3> The proteinuria and the percent of kidney crescent formation index of LN group was significantly high than oher three groups. Exosomes can be absorbed by mesangial cells quickly. The secrection of inflammatory cytokines and collagen Iof LN group were higher than NLN and control group(p&lt;0.05).PI3K/AKT pathway are involved, But there was no significant difference between NLN group and control group. High-throughput sequencing revealed 11 up-regulated miRNA in SLE relative LN,3 up-regulated miRNA in LN relative healthy people. <h3>Conclusions</h3> LN exosomes can enhance the proliferation and secrection of mesangial cells in which PI3K/AKT pathway is actived. This tip us exosomes may involve in the pathogenesis of LN. <h3>References</h3> [1] Shen B, Tan W, Feng G, He Y, Liu J, Chen W, Huang X, Da Z, Xu X, Liu H, Gu Z. The correlations of disease activity, socioeconomic status, quality of life, and depression/anxiety in Chinese patients with systemic lupus erythematosus. Clinical &amp; developmental immunology2013;270878. [2] Chafin CB, Reilly CM. MicroRNAs implicated in the immunopathogenesis of lupus nephritis. Clinical &amp; developmental immunology2013;430239. [3] Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. Cellular and molecular neurobiology2016. <h3>Acknowledgements</h3> The Natural Science Foundation of China under Grant (81202368), The Natural Science Foundation of China under Grant (81471603) <h3>Disclosure of Interest</h3> None declared
THU0480 Multi-disciplinary fracture liaison service in the north area of gran canaria; 6 years experience
Authors: A. Naranjo, S. Ojeda, S. Rodríguez, A. Saavedra, F. Santana, A. Molina, A. Gonzalez, N. Martin, M. Afonso, C. Dominguez, I. Beirutti, O. Suarez, T. Marrero, C. Rodriguez-Lozano
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> in March 2012 was implemented a FLS Unit coordinated by Rheumatology <h3>Objectives</h3> communicate the results of the unit in the 2012–2017 period. <h3>Methods</h3> Patients&gt;50 years with fragility fracture. The program consists of: 1) training of primary care doctors (GP), 2) recruitment from the emergency room or admitted with hip fracture; 3) Bone densitometry; 4) patient education by a nurse; 6) report to GP with recommendations of managing; and 7) follow-up of persistence of treatment (telephonic survey plus prescription in the electronic records) at 3, 6, 12 and 24 months. <h3>Results</h3> The FLS has attended 1739 patients: mean age 73 y, 81% women. The location of fractures was forearm (32%), hip (24%), humerus (21%), vertebra (10%) and other locations (12%). Previous treatment with bisphosphonate 17%, 10% of them at baseline. After the baseline visit, 75% of patients were sent to GP and 25% to rheumatology. Treatment with bisphosphonate or equivalent was recommended to 1264 patients (72%). Persistence of treatment (analysed at 3, 6, 12 and 24 months in 1,051, 823, 622 and 351 patients, respectively) was 74%, 72%, 75% and 69%, respectively. <h3>Conclusions</h3> Our FLS is effective in terms of beginning and persistence of antifracture treatment in the medium term. <h3>Disclosure of Interest</h3> None declared
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Authors: Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch, Maria Dolores Caballero Barrigón, Andrzej Hellmann, Bryone Kuss, David D F Ma, Fatih Demirkan, Münci Yağci, Netanel A Horowitz, Paula Marlton, Raul Cordoba, Tomasz Wrobel, Daniela Buglio, Michael Streit, Brendan P Hodkinson, Michael Schaffer, John Alvarez, Rob Ceulemans, Sriram Balasubramanian, Jan de Jong, Shean-Sheng Wang, Nele Fourneau, Wojciech Jurczak
Journal: The Lancet Haematology (2019)
Abstract 15632: Mildly Elevated Aspartate Aminotransferase Levels Predict Stroke Deaths in a General Japanese Population
Authors: Hisako Tsuji, Ichiro Shiojima
Journal: Circulation (2017)

Background: Liver disease and cirrhosis have been associated with an increased risk of stroke, especially risk of hemorrhagic stroke, but there was a report that could not find the association. We ...
APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM
Authors: Yu-Tzu Tai, John Dulos, Lars Guelen, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Tengteng Yu, Phillip A Hsieh, Peter van Zandvoort, Guido van de Wiel, Jos van de Crommert, Bonny Lejeune, Hamid Namini, Hans Eenennaam, Andrea van Elsas, Paul Richardson, Nikhil Munshi, Kenneth C. Anderson
Journal: Blood (2018)